- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.05. | Polyrizon signs first clinical trial agreement for allergy drug | 1 | Investing.com | ||
| 13.05. | Polyrizon Ltd.: Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX Allergy Blocker Clinical Trial | 1 | GlobeNewswire (USA) | ||
| 13.05. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 04.05. | Polyrizon submits amended claims for intranasal drug delivery patent | 1 | Investing.com | ||
| 04.05. | Polyrizon erweitert Patentansprüche für intranasale Wirkstoffplattform | 1 | Investing.com Deutsch | ||
| 04.05. | Polyrizon Ltd.: Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform | 146 | GlobeNewswire (Europe) | Raanana, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 04.05. | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| 27.04. | Polyrizon Ltd.: Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform | 366 | GlobeNewswire (Europe) | Raanana, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative... ► Artikel lesen | |
| 27.04. | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.04. | Polyrizon Ltd. - F-1, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 08.04. | Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements | 1 | GlobeNewswire (USA) | ||
| 08.04. | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 07.04. | Polyrizon beschafft 3,5 Mio. US-Dollar über registrierte Direktplatzierung | 2 | Investing.com Deutsch | ||
| 07.04. | Polyrizon sichert sich 3,5 Mio. US-Dollar über Direktplatzierung | 1 | Investing.com Deutsch | ||
| 07.04. | Polyrizon raises $3.5M through registered direct offering | 1 | Investing.com | ||
| 26.03. | Polyrizon reports $17.5M cash position, advances FDA discussions | 1 | Investing.com | ||
| 26.03. | Polyrizon Ltd.: Polyrizon Provides 2025 and Recent Highlights | 221 | GlobeNewswire (Europe) | Raanana, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions... ► Artikel lesen | |
| 26.03. | Polyrizon reports FY results: GAAP EPS of $4.90 | 1 | Seeking Alpha | ||
| 25.03. | Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 | 5 | GlobeNewswire (USA) | ||
| 25.03. | Polyrizon Ltd. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings |
1 2 3 4 5 Weiter >>
90 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 30,095 | +0,62 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| NOVAVAX | 7,760 | -2,63 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 14,380 | -1,17 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| BIOXXMED | 0,800 | 0,00 % | PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH | DJ PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Heidelberg (pta000/09.03.2026/13:50... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,132 | +5,70 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| COSCIENS BIOPHARMA | 1,400 | -6,04 % | COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer | ||
| XOMA ROYALTY | 35,600 | -1,66 % | Ligand Pharmaceuticals und XOMA Royalty passen Fusionsvereinbarung an | ||
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| PHIO PHARMACEUTICALS | 1,090 | +2,83 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update | Key Development Agreements Secured for Nonclinical Toxicology and U.S. cGMP Clinical Supply ManufacturingKing of Prussia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Phio Pharmaceuticals Corp.... ► Artikel lesen | |
| ORAGENICS | 0,580 | +0,16 % | ORAGENICS INC - 8-K, Current Report | ||
| VIVUS | - | - | VIVUS B.V.: VIVUS Reinforces QSIVA's Clinical Efficacy and Safety in Obesity Management | - QSIVA offers clinically meaningful weight loss supported by a well-established safety profile, now available at a reduced price across Nordics and Poland
AMSTERDAM, March 25, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| TENAX THERAPEUTICS | 9,500 | +7,34 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer | CHAPEL HILL, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company... ► Artikel lesen | |
| UNITY BIOTECHNOLOGY | 0,030 | 0,00 % | Unity Biotechnology, Inc. - 15-12G, Securities registration termination | ||
| SERES THERAPEUTICS | 6,500 | -0,46 % | Seres Therapeutics, Inc.: Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | Readout of investigator-sponsored SER-155 study in immune checkpoint-related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track... ► Artikel lesen |
Das Unternehmen POLYRIZON LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,18 % bei einem Aktienkurs von 13,395 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.